| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-104 |
Sentence |
denotes |
Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease. |
| T1 |
0-104 |
Sentence |
denotes |
Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease. |
| T2 |
105-282 |
Sentence |
denotes |
[6-2H2]Glucose was used as a tracer for a comparative study on the metabolism of the neutral glycosylceramides in plasma of a control subject and a patient with Fabry's disease. |
| T2 |
105-282 |
Sentence |
denotes |
[6-2H2]Glucose was used as a tracer for a comparative study on the metabolism of the neutral glycosylceramides in plasma of a control subject and a patient with Fabry's disease. |
| T3 |
283-487 |
Sentence |
denotes |
The incorporation of the tracer into the glucosyl and galactosyl moieties of the glycosphingolipids was measured by gas chromatography-mass spectrometry of the tetra-0-acetyl methyl glycoside derivatives. |
| T3 |
283-487 |
Sentence |
denotes |
The incorporation of the tracer into the glucosyl and galactosyl moieties of the glycosphingolipids was measured by gas chromatography-mass spectrometry of the tetra-0-acetyl methyl glycoside derivatives. |
| T4 |
488-704 |
Sentence |
denotes |
Experiments on the precision and accuracy for measurements of [6,6-2H2]hexose in a sample demonstrated that incorporation of 0.2% or more of [6,6-2H2]glucose could be detected with a 95% confidence limit of +/-0.16%. |
| T4 |
488-704 |
Sentence |
denotes |
Experiments on the precision and accuracy for measurements of [6,6-2H2]hexose in a sample demonstrated that incorporation of 0.2% or more of [6,6-2H2]glucose could be detected with a 95% confidence limit of +/-0.16%. |
| T5 |
705-871 |
Sentence |
denotes |
The labeled substrate (35g) was infused into each subject with a 5-g priming dose and the remainder administered at a constant rate of 3 g/hour over a 10-hour period. |
| T5 |
705-871 |
Sentence |
denotes |
The labeled substrate (35g) was infused into each subject with a 5-g priming dose and the remainder administered at a constant rate of 3 g/hour over a 10-hour period. |
| T6 |
872-1059 |
Sentence |
denotes |
During the infusion, the plasma glucose of each subject attained a concentration of about 30% [6,6-2H2]glucose which diminished rapidly after the administration of substrate was complete. |
| T6 |
872-1059 |
Sentence |
denotes |
During the infusion, the plasma glucose of each subject attained a concentration of about 30% [6,6-2H2]glucose which diminished rapidly after the administration of substrate was complete. |
| T7 |
1060-1220 |
Sentence |
denotes |
A concentration of 0.8% [6,6-2H2]glucose was observed in glucosylceramide (GL-la) from plasma of both subjects between 48 and 72 hours after the infusion began. |
| T7 |
1060-1220 |
Sentence |
denotes |
A concentration of 0.8% [6,6-2H2]glucose was observed in glucosylceramide (GL-la) from plasma of both subjects between 48 and 72 hours after the infusion began. |
| T8 |
1221-1362 |
Sentence |
denotes |
The label disappeared from this lipid at a logarithmic rate and 0.2% or less of the molecules were labeled 9 days after the experiment began. |
| T8 |
1221-1362 |
Sentence |
denotes |
The label disappeared from this lipid at a logarithmic rate and 0.2% or less of the molecules were labeled 9 days after the experiment began. |
| T9 |
1363-1591 |
Sentence |
denotes |
In contrast to the results with GL-la, the maximum incorporation of [6,6-2H2]hexose into lactosylceramide (galactosyl-(beta1 leads to 4)-glucosylceramide) was 2-fold higher in the Fabry patient (1.6%) than in the control (0.8%). |
| T9 |
1363-1591 |
Sentence |
denotes |
In contrast to the results with GL-la, the maximum incorporation of [6,6-2H2]hexose into lactosylceramide (galactosyl-(beta1 leads to 4)-glucosylceramide) was 2-fold higher in the Fabry patient (1.6%) than in the control (0.8%). |
| T10 |
1592-1887 |
Sentence |
denotes |
The trihexosylceramide (galactosyl-(alpha1 leads to 4)-galactosyl-(beta1 leads to 4)-glucosylceramide, GL-3a) from plasma of the control reached a maximum of 0.4% [6,6-2H2]hexose in both the glucosyl and galactosyl moieties whereas the GL-3a from the Fabry patient was not significantly labeled. |
| T10 |
1592-1887 |
Sentence |
denotes |
The trihexosylceramide (galactosyl-(alpha1 leads to 4)-galactosyl-(beta1 leads to 4)-glucosylceramide, GL-3a) from plasma of the control reached a maximum of 0.4% [6,6-2H2]hexose in both the glucosyl and galactosyl moieties whereas the GL-3a from the Fabry patient was not significantly labeled. |
| T11 |
1888-2081 |
Sentence |
denotes |
The maximal labeling of the GL-4a fraction (N-acetyl-galactosaminyl-galactosyl-galactosyl-glucosylceramide) was slightly depressed in the Fabry patient (0.4%) as compared to the control (0.7%). |
| T11 |
1888-2081 |
Sentence |
denotes |
The maximal labeling of the GL-4a fraction (N-acetyl-galactosaminyl-galactosyl-galactosyl-glucosylceramide) was slightly depressed in the Fabry patient (0.4%) as compared to the control (0.7%). |
| T12 |
2082-2223 |
Sentence |
denotes |
Turnover times for the glycosphingolipids of plasma were calculated to be from 4 to 8 days and the turnover rates were from 1 to 6 mumol/day. |
| T12 |
2082-2223 |
Sentence |
denotes |
Turnover times for the glycosphingolipids of plasma were calculated to be from 4 to 8 days and the turnover rates were from 1 to 6 mumol/day. |